Search

Your search keyword '"Wang, Y. Lynn"' showing total 307 results
Start Over Author "Wang, Y. Lynn"
307 results on '"Wang, Y. Lynn"'

3. Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing

Author

Fernandez, Sandra V., primary, Tan, Yin Fei, additional, Rao, Shilpa, additional, Fittipaldi, Patricia, additional, Sheriff, Fathima, additional, Borghaei, Hossein, additional, Dotan, Efrat, additional, Winn, Jennifer S., additional, Edelman, Martin J., additional, Treat, Joseph, additional, Judd, Julia, additional, Alpaugh, R. Katherine, additional, Wang, Y. Lynn, additional, Yu, Jian Q., additional, Wasik, Mariusz, additional, and Baldwin, Don A., additional

Published
2023
Full Text
View/download PDF

4. Multiple Genomic Alterations, Including a Novel AFF4::IRF1 Fusion Gene, in a Treatment-Refractory Blastic Plasmacytoid Dendritic-Cell Neoplasm: A Case Report and Literature Review.

Author

Sahin, Yavuz, Wang, Y. Lynn, Pei, Jianming, Mansoor, Nashwa, Styler, Michael, Testa, Joseph R., and Nejati, Reza

Subjects
*LITERATURE reviews, *GENE fusion, *SOMATIC mutation, *TUMORS, *HEMATOLOGIC malignancies
Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with an aggressive clinical course and poor prognosis. The genetic abnormalities in BPDCN are heterogeneous; therefore, its molecular pathogenesis and the prognostic importance of genomic alterations associated with the disease are not well defined. Here we report a case of BPDCN with a novel AFF4::IRF1 fusion predicted to lead to a loss-of-function of the IRF1 tumor suppressor, somatic mutations of ASXL1, TET2, and MYD88, as well as multiple intrachromosomal deletions. The patient showed resistance to Tagraxofusp and Venetoclax, and he died about 16 months after diagnosis. Considering the predicted effect of the AFF4::IRF1 fusion on IRF1's antitumor effects and immune regulation, and the possibility of its relevance to the aggressive course observed in this case, we propose further evaluation of the clinical significance of this fusion in BPDCN in future cooperative group studies and the consideration of therapeutic strategies aimed at restoring IRF1-dependent antineoplastic effects in such cases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Supplementary figures 1-3 from XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB

Author

Ming, Mei, primary, Wu, Wenjun, primary, Xie, Bingqing, primary, Sukhanova, Madina, primary, Wang, Weige, primary, Kadri, Sabah, primary, Sharma, Shruti, primary, Lee, Jimmy, primary, Shacham, Sharon, primary, Landesman, Yosef, primary, Maltsev, Natalia, primary, Lu, Pin, primary, and Wang, Y. Lynn, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Materials from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Author

Zhang, Leo, primary, Nomie, Krystle, primary, Zhang, Hui, primary, Bell, Taylor, primary, Pham, Lan, primary, Kadri, Sabah, primary, Segal, Jeremy, primary, Li, Shaoying, primary, Zhou, Shouhao, primary, Santos, David, primary, Richard, Shawana, primary, Sharma, Shruti, primary, Chen, Wendy, primary, Oriabure, Onyekachukwu, primary, Liu, Yang, primary, Huang, Shengjian, primary, Guo, Hui, primary, Chen, Zhihong, primary, Tao, Wenjing, primary, Li, Carrie, primary, Wang, Jack, primary, Fang, Bingliang, primary, Wang, Jacqueline, primary, Li, Lei, primary, Badillo, Maria, primary, Ahmed, Makhdum, primary, Thirumurthi, Selvi, primary, Huang, Steven Y., primary, Shao, Yiping, primary, Lam, Laura, primary, Yi, Qing, primary, Wang, Y. Lynn, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure S3. Treatment profiling of PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Author

Zhang, Leo, primary, Nomie, Krystle, primary, Zhang, Hui, primary, Bell, Taylor, primary, Pham, Lan, primary, Kadri, Sabah, primary, Segal, Jeremy, primary, Li, Shaoying, primary, Zhou, Shouhao, primary, Santos, David, primary, Richard, Shawana, primary, Sharma, Shruti, primary, Chen, Wendy, primary, Oriabure, Onyekachukwu, primary, Liu, Yang, primary, Huang, Shengjian, primary, Guo, Hui, primary, Chen, Zhihong, primary, Tao, Wenjing, primary, Li, Carrie, primary, Wang, Jack, primary, Fang, Bingliang, primary, Wang, Jacqueline, primary, Li, Lei, primary, Badillo, Maria, primary, Ahmed, Makhdum, primary, Thirumurthi, Selvi, primary, Huang, Steven Y., primary, Shao, Yiping, primary, Lam, Laura, primary, Yi, Qing, primary, Wang, Y. Lynn, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table S3. OncoPlus Gene List and Identified Variants from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Author

Zhang, Leo, primary, Nomie, Krystle, primary, Zhang, Hui, primary, Bell, Taylor, primary, Pham, Lan, primary, Kadri, Sabah, primary, Segal, Jeremy, primary, Li, Shaoying, primary, Zhou, Shouhao, primary, Santos, David, primary, Richard, Shawana, primary, Sharma, Shruti, primary, Chen, Wendy, primary, Oriabure, Onyekachukwu, primary, Liu, Yang, primary, Huang, Shengjian, primary, Guo, Hui, primary, Chen, Zhihong, primary, Tao, Wenjing, primary, Li, Carrie, primary, Wang, Jack, primary, Fang, Bingliang, primary, Wang, Jacqueline, primary, Li, Lei, primary, Badillo, Maria, primary, Ahmed, Makhdum, primary, Thirumurthi, Selvi, primary, Huang, Steven Y., primary, Shao, Yiping, primary, Lam, Laura, primary, Yi, Qing, primary, Wang, Y. Lynn, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure S2. Characterization of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Author

Zhang, Leo, primary, Nomie, Krystle, primary, Zhang, Hui, primary, Bell, Taylor, primary, Pham, Lan, primary, Kadri, Sabah, primary, Segal, Jeremy, primary, Li, Shaoying, primary, Zhou, Shouhao, primary, Santos, David, primary, Richard, Shawana, primary, Sharma, Shruti, primary, Chen, Wendy, primary, Oriabure, Onyekachukwu, primary, Liu, Yang, primary, Huang, Shengjian, primary, Guo, Hui, primary, Chen, Zhihong, primary, Tao, Wenjing, primary, Li, Carrie, primary, Wang, Jack, primary, Fang, Bingliang, primary, Wang, Jacqueline, primary, Li, Lei, primary, Badillo, Maria, primary, Ahmed, Makhdum, primary, Thirumurthi, Selvi, primary, Huang, Steven Y., primary, Shao, Yiping, primary, Lam, Laura, primary, Yi, Qing, primary, Wang, Y. Lynn, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Author

Zhang, Leo, primary, Nomie, Krystle, primary, Zhang, Hui, primary, Bell, Taylor, primary, Pham, Lan, primary, Kadri, Sabah, primary, Segal, Jeremy, primary, Li, Shaoying, primary, Zhou, Shouhao, primary, Santos, David, primary, Richard, Shawana, primary, Sharma, Shruti, primary, Chen, Wendy, primary, Oriabure, Onyekachukwu, primary, Liu, Yang, primary, Huang, Shengjian, primary, Guo, Hui, primary, Chen, Zhihong, primary, Tao, Wenjing, primary, Li, Carrie, primary, Wang, Jack, primary, Fang, Bingliang, primary, Wang, Jacqueline, primary, Li, Lei, primary, Badillo, Maria, primary, Ahmed, Makhdum, primary, Thirumurthi, Selvi, primary, Huang, Steven Y., primary, Shao, Yiping, primary, Lam, Laura, primary, Yi, Qing, primary, Wang, Y. Lynn, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure S4. Carfilzomib overcomes primary ibrutinib resistance in vivo from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Author

Zhang, Leo, primary, Nomie, Krystle, primary, Zhang, Hui, primary, Bell, Taylor, primary, Pham, Lan, primary, Kadri, Sabah, primary, Segal, Jeremy, primary, Li, Shaoying, primary, Zhou, Shouhao, primary, Santos, David, primary, Richard, Shawana, primary, Sharma, Shruti, primary, Chen, Wendy, primary, Oriabure, Onyekachukwu, primary, Liu, Yang, primary, Huang, Shengjian, primary, Guo, Hui, primary, Chen, Zhihong, primary, Tao, Wenjing, primary, Li, Carrie, primary, Wang, Jack, primary, Fang, Bingliang, primary, Wang, Jacqueline, primary, Li, Lei, primary, Badillo, Maria, primary, Ahmed, Makhdum, primary, Thirumurthi, Selvi, primary, Huang, Steven Y., primary, Shao, Yiping, primary, Lam, Laura, primary, Yi, Qing, primary, Wang, Y. Lynn, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Data (Table S1, Figure S1, Figure S2, Figure S3) from Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

Author

Coffey, Greg P., primary, Feng, Jiajia, primary, Betz, Andreas, primary, Pandey, Anjali, primary, Birrell, Matt, primary, Leeds, Janet M., primary, Der, Kenneth, primary, Kadri, Sabah, primary, Lu, Pin, primary, Segal, Jeremy, primary, Wang, Y. Lynn, primary, Michelson, Glenn, primary, Curnutte, John T., primary, and Conley, Pamela B., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table S2. The RPPA antibody list from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Author

Zhang, Leo, primary, Nomie, Krystle, primary, Zhang, Hui, primary, Bell, Taylor, primary, Pham, Lan, primary, Kadri, Sabah, primary, Segal, Jeremy, primary, Li, Shaoying, primary, Zhou, Shouhao, primary, Santos, David, primary, Richard, Shawana, primary, Sharma, Shruti, primary, Chen, Wendy, primary, Oriabure, Onyekachukwu, primary, Liu, Yang, primary, Huang, Shengjian, primary, Guo, Hui, primary, Chen, Zhihong, primary, Tao, Wenjing, primary, Li, Carrie, primary, Wang, Jack, primary, Fang, Bingliang, primary, Wang, Jacqueline, primary, Li, Lei, primary, Badillo, Maria, primary, Ahmed, Makhdum, primary, Thirumurthi, Selvi, primary, Huang, Steven Y., primary, Shao, Yiping, primary, Lam, Laura, primary, Yi, Qing, primary, Wang, Y. Lynn, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

20. Resistance to BTK inhibition in CLL and non-Hodgkin lymphoma

Author

Nakhoda, Shazia, Vistarop, Aldana, and Wang, Y. Lynn

Subjects
Article
Abstract

Bruton tyrosine kinase inhibitors (BTKi) have transformed the therapeutic landscape of chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL). However, primary and acquired resistance to BTKi can be seen due to a variety of mechanisms including tumor intrinsic and extrinsic mechanisms such as gene mutations, activation of bypass signaling pathways, and tumor microenvironment. Herein, we provide an updated review of the key clinical data of BTKi treatment in CLL, mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). We incorporate the most recent findings regarding mechanisms of resistance to covalent and non-covalent inhibitors, including ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib. We also cover the clinical sensitivity of certain molecular subtypes of DLBCL to an ibrutinib-containing regimen. Lastly, we summarize ongoing clinical investigations aimed at overcoming resistance via use of BTKi-containing combination therapies or the novel non-covalent BTK inhibitors. The review article targets an audience of clinical practitioners, clinical investigators, and translational researchers.

Published
2022

24. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma.

Author

Nakhoda, Shazia, Vistarop, Aldana, and Wang, Y. Lynn

Subjects
BRUTON tyrosine kinase, CHRONIC leukemia, LYMPHOCYTIC leukemia, NON-Hodgkin's lymphoma, DIFFUSE large B-cell lymphomas
Abstract

Summary: Bruton tyrosine kinase inhibitors (BTKi) have transformed the therapeutic landscape of chronic lymphocytic leukaemia (CLL) and non‐Hodgkin lymphoma. However, primary and acquired resistance to BTKi can be seen due to a variety of mechanisms including tumour intrinsic and extrinsic mechanisms such as gene mutations, activation of bypass signalling pathways and tumour microenvironment. Herein, we provide an updated review of the key clinical data of BTKi treatment in CLL, mantle cell lymphoma, and diffuse large B‐cell lymphoma (DLBCL). We incorporate the most recent findings regarding mechanisms of resistance to covalent and non‐covalent inhibitors, including ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib. We also cover the clinical sensitivity of certain molecular subtypes of DLBCL to an ibrutinib‐containing regimen. Lastly, we summarise ongoing clinical investigations aimed at overcoming resistance via use of BTKi‐containing combined therapies or the novel non‐covalent BTKi. The review article targets an audience of clinical practitioners, clinical investigators and translational researchers. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Author

Branford, Susan, Fletcher, Linda, Cross, Nicholas C.P., Müller, Martin C., Hochhaus, Andreas, Kim, Dong-Wook, Radich, Jerald P., Saglio, Giuseppe, Pane, Fabrizio, Kamel-Reid, Suzanne, Wang, Y. Lynn, Press, Richard D., Lynch, Kevin, Rudzki, Zbigniew, Goldman, John M., and Hughes, Timothy

Published
2008
Full Text
View/download PDF

40. Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication

Author

Wang, Y. Lynn Lynn, primary, Franzen, Carrie, primary, Wang, Shengchun, primary, Venkataraman, Girish, primary, Li, Lei, primary, Niu, Nifang, primary, Sukhanova, Madina, primary, Tu, Yifan, primary, Gao, Juehua, primary, Chen, Yi-Hua, primary, Ma, Shuo, primary, Larson, Richard A., primary, and Pin, Lu, primary

Published
2019
Full Text
View/download PDF

42. Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells

Author

Lee, Seung-Cheol, primary, Shestov, Alexander A., additional, Guo, Lili, additional, Zhang, Qian, additional, Roman, Jeffrey C., additional, Liu, Xiaobin, additional, Wang, Hong Y., additional, Pickup, Stephen, additional, Nath, Kavindra, additional, Lu, Pin, additional, Hofbauer, Samuel, additional, Mesaros, Clementina, additional, Wang, Y. Lynn, additional, Nelson, David S., additional, Schuster, Stephen J., additional, Blair, Ian A., additional, Glickson, Jerry D., additional, and Wasik, Mariusz A., additional

Published
2019
Full Text
View/download PDF

43. Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

Author

Coffey, Greg P., primary, Feng, Jiajia, additional, Betz, Andreas, additional, Pandey, Anjali, additional, Birrell, Matt, additional, Leeds, Janet M., additional, Der, Kenneth, additional, Kadri, Sabah, additional, Lu, Pin, additional, Segal, Jeremy, additional, Wang, Y. Lynn, additional, Michelson, Glenn, additional, Curnutte, John T., additional, and Conley, Pamela B., additional

Published
2019
Full Text
View/download PDF

44. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB

Author

Ming, Mei, primary, Wu, Wenjun, additional, Xie, Bingqing, additional, Sukhanova, Madina, additional, Wang, Weige, additional, Kadri, Sabah, additional, Sharma, Shruti, additional, Lee, Jimmy, additional, Shacham, Sharon, additional, Landesman, Yosef, additional, Maltsev, Natalia, additional, Lu, Pin, additional, and Wang, Y. Lynn, additional

Published
2018
Full Text
View/download PDF

45. Inhibition of B-Cell Receptor Signaling Disrupts Cell Adhesion in Mantle Cell Lymphoma Via RAC2

Author

Wang, Weige, primary, Carrie, Franzen, additional, Guo, Hui, additional, Lee, Jimmy, additional, Li, Yan, additional, Sukhanova, Madina, additional, Sheng, Dong, additional, Venkataraman, Girish, additional, Mei, Ming, additional, Lu, Pin, additional, Gao, Anhui, additional, Xia, Chunmei, additional, Jia, Li, additional, Zhang, Liang, additional, Wang, Michael, additional, Andrade, Jorge, additional, Xiaoyan, Zhou, additional, and Wang, Y. Lynn Lynn, additional

Published
2018
Full Text
View/download PDF

46. TP53 Aberrations By FISH in CLL and Complex Karyotype at Transformation Predict for Worse Outcome in Diffuse Large B-Cell Lymphoma - Richter Transformation: A Single Institution Series of 75 DLBCL-RT Cases

Author

Fidai, Shiraz, primary, Sukhanova, Madina, additional, Chiu, Brian C.-H., additional, Wang, Y. Lynn Lynn, additional, Stock, Wendy, additional, Riedell, Peter A, additional, Smith, Sonali M., additional, Hyjek, Elizabeth, additional, and Venkataraman, Girish, additional

Published
2018
Full Text
View/download PDF

47. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

Author

Lee, Jimmy, primary, Zhang, Liang Leo, primary, Wu, Wenjun, primary, Guo, Hui, primary, Li, Yan, primary, Sukhanova, Madina, primary, Venkataraman, Girish, primary, Huang, Shengjian, primary, Zhang, Hui, primary, Alikhan, Mir, primary, Lu, Pin, primary, Guo, Ailin, primary, Galanina, Natalie, primary, Andrade, Jorge, primary, Wang, Michael L., primary, and Wang, Y. Lynn, primary

Published
2018
Full Text
View/download PDF

48. System for Informatics in the Molecular Pathology Laboratory

Author

Kang, Wenjun, primary, Kadri, Sabah, additional, Puranik, Rutika, additional, Wurst, Michelle N., additional, Patil, Sushant A., additional, Mujacic, Ibro, additional, Benhamed, Sonia, additional, Niu, Nifang, additional, Zhen, Chao Jie, additional, Ameti, Bekim, additional, Long, Bradley C., additional, Galbo, Filipo, additional, Montes, David, additional, Iracheta, Crystal, additional, Gamboa, Venessa L., additional, Lopez, Daisy, additional, Yourshaw, Michael, additional, Lawrence, Carolyn A., additional, Aisner, Dara L., additional, Fitzpatrick, Carrie, additional, McNerney, Megan E., additional, Wang, Y. Lynn, additional, Andrade, Jorge, additional, Volchenboum, Samuel L., additional, Furtado, Larissa V., additional, Ritterhouse, Lauren L., additional, and Segal, Jeremy P., additional

Published
2018
Full Text
View/download PDF

50. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Author

Zhang, Leo, primary, Nomie, Krystle, additional, Zhang, Hui, additional, Bell, Taylor, additional, Pham, Lan, additional, Kadri, Sabah, additional, Segal, Jeremy, additional, Li, Shaoying, additional, Zhou, Shouhao, additional, Santos, David, additional, Richard, Shawana, additional, Sharma, Shruti, additional, Chen, Wendy, additional, Oriabure, Onyekachukwu, additional, Liu, Yang, additional, Huang, Shengjian, additional, Guo, Hui, additional, Chen, Zhihong, additional, Tao, Wenjing, additional, Li, Carrie, additional, Wang, Jack, additional, Fang, Bingliang, additional, Wang, Jacqueline, additional, Li, Lei, additional, Badillo, Maria, additional, Ahmed, Makhdum, additional, Thirumurthi, Selvi, additional, Huang, Steven Y., additional, Shao, Yiping, additional, Lam, Laura, additional, Yi, Qing, additional, Wang, Y. Lynn, additional, and Wang, Michael, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results